8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 26, 2012

Illumina, Inc.

__________________________________________

(Exact name of registrant as specified in its charter)

Delaware	001-35406	33-0804655
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
5200 Illumina Way, San Diego, California		92122
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: (858) 202-4500

______________________________________________

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of November 26, 2012, the Board of Directors (the "Board") of Illumina, Inc. (the "Company") increased the size of the Board from nine to ten members and elected Robert S. Epstein, M.D., to serve on the Board. Dr. Epstein has been assigned to serve in the class of directors currently including Messrs. Daniel M. Bradbury and Roy A. Whitfield, and, consistent with the Company's Corporate Governance Guidelines, Dr. Epstein will stand for election by the Company's stockholders at the Company's 2013 annual meeting of stockholders to serve for a one-year term commencing with such meeting. There is no arrangement or understanding between Dr. Epstein and any other person pursuant to which he was selected as a director. In addition, Dr. Epstein is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Dr. Epstein will participate in the non-employee director compensation programs described under "Director Compensation" in the Company's proxy statement filed on March 19, 2012. A copy of the Company's press release announcing Dr. Epstein's appointment is filed as Exhibit 99.1 to this Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ILLUMINA, INC.
Date: November 29, 2012	By:	/s/ Christian G. Cabou
		Name: Christian G. Cabou
		Title: Senior Vice President & General Counsel

Exhibit Index

Exhibit No.	Description
99.1	Press Release, dated November 29, 2012

EX-99.1

Illumina Names Dr. Robert S. Epstein to its Board of Directors

SAN DIEGO, November 29, 2012 - Illumina, Inc. (NASDAQ: ILMN) today announced that Dr. Robert S. Epstein, M.D., has joined the company's Board of Directors. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector.

Previously, from 2010 to 2012, Dr. Epstein was Chief R&D Officer and President of Medco-UBC, a 2,400 person global research organization focused on conducting personalized medicine, health economics, drug safety, outcomes, and comparative effectiveness research on behalf of the biopharmaceutical, medical device, and diagnostics industries. Prior to this role, Dr. Epstein was Medco's Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. In addition, Dr. Epstein is the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life. Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA.

“We are delighted to welcome Rob to the Illumina Board, and excited by the prospect of working with this dynamic leader to advance personalized medicine,” said Jay Flatley, Illumina's President and CEO. “Benefitting from Rob's perspective and expertise, at this critical time when scientific and technological advances in genetic research and biomedicine are beginning to transform healthcare, will be invaluable as Illumina pursues its clinical diagnostic growth strategy.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Source: Illumina, Inc.

Illumina, Inc.

Investors:

Rebecca Chambers

Investor Relations

858-255-5243

rchambers@illumina.com

or

Media:

Jennifer Temple

Public Relations

858-882-6822

pr@illumina.com